Neurologic complications in kidney transplant recipients

被引:24
作者
Piotrowski, Piotr C. [1 ,2 ]
Lutkowska, Anna [2 ]
Tsibulski, Alexander [2 ]
Karczewski, Marek [3 ]
Jagodzinski, Pawet P. [2 ]
机构
[1] Polish Acad Sci, Dept Expt & Clin Neuropathol, Mossakowski Med Res Ctr, 5 Pawinskiego St, PL-02106 Warsaw, Poland
[2] Poznan Univ Med Sci, Dept Biochem & Mol Biol, Poznan, Poland
[3] Poznan Univ Med Sci, Dept Transplantol Gen Vasc & Plast Surg, Clin Hosp, Poznan, Poland
关键词
kidney transplantation; immunosuppression; neurotoxicity; PTLD; PRES; opportunistic infections; CNS; CENTRAL-NERVOUS-SYSTEM; REVERSIBLE ENCEPHALOPATHY SYNDROME; INVASIVE FUNGAL-INFECTIONS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; ORTHOTOPIC LIVER-TRANSPLANTATION; CORTICOSTEROID-INDUCED MYOPATHY; BONE-MARROW-TRANSPLANTATION; ACUTE FEMORAL NEUROPATHY; ONSET DIABETES-MELLITUS; CALCINEURIN INHIBITORS;
D O I
10.5114/fn.2017.68577
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Transplantology experiences continuous growth and kidney transplantation is the most frequently transplanted solid organ. Metabolic, cardiovascular, infectious or kidney function-related aspects are widely recognised and are of key interest for transplant doctors. Neurological complications seen in these patients, although known, are less covered in the literature. According to some reports, neurologic symptoms are experienced by almost 9 per 10 transplant recipients. The intensity, severity and type of abnormalities may vary, and most frequently the complications seem to be associated with a direct or indirect effect of immunosuppressive medications, including their direct effect on cells, on blood vessels, and susceptibility to infections. Increasing age of transplant recipients and relaxation of transplantation eligibility criteria enriches the population with patients already compromised, with a higher present risk of stroke, neuropathy, malignancy etc. Research on and introduction to clinical practice of new agents like belatacept, proteasome inhibitors, or modified release formulations of tacrolimus, changes the picture and type of abnormalities within the nervous or neuromuscular system but does not eliminate them. Thus, it seems justified to remind the society of the whole array of neurologic complications they can see in their practice despite advances in the field.
引用
收藏
页码:86 / 109
页数:24
相关论文
共 243 条
[1]   Cerebrovascular Events in Renal Transplant Recipients [J].
Abedini, Sadollah ;
Holme, Ingar ;
Fellstrom, Bengt ;
Jardine, Alan ;
Cole, Edward ;
Maes, Bart ;
Holdaas, Hallvard .
TRANSPLANTATION, 2009, 87 (01) :112-117
[2]   The role of mTOR in depression and antidepressant responses [J].
Abelaira, Helena M. ;
Reus, Gislaine Z. ;
Neotti, Morgana V. ;
Quevedo, Joao .
LIFE SCIENCES, 2014, 101 (1-2) :10-14
[3]  
Abramowicz D, 1996, KIDNEY INT, V49, pS39
[4]   STROKE IN RENAL-TRANSPLANT RECIPIENTS [J].
ADAMS, HP ;
DAWSON, G ;
COFFMAN, TJ ;
CORRY, RJ .
ARCHIVES OF NEUROLOGY, 1986, 43 (02) :113-115
[5]  
Ahmed S, 2012, J PAK MED ASSOC, V62, P1326
[6]   Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: Results at 2 years [J].
Ahsan, N ;
Johnson, C ;
Gonwa, T ;
Halloran, P ;
Stegall, M ;
Hardy, M ;
Metzger, R ;
Shield, C ;
Rocher, L ;
Scandling, J ;
Sorensen, J ;
Mulloy, L ;
Light, J ;
Corwin, C ;
Danovitch, G ;
Wachs, M ;
VanVeldhuisen, P ;
Salm, K ;
Tolzman, D ;
Fitzsimmons, WE .
TRANSPLANTATION, 2001, 72 (02) :245-250
[7]   Post-Transplant Lymphoproliferative Disease (PTLD): Risk Factors, Diagnosis, and Current Treatment Strategies [J].
Al-Mansour, Zeina ;
Nelson, Beverly P. ;
Evens, Andrew M. .
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2013, 8 (03) :173-183
[8]   Short-term treatment with the calcineurin inhibitor cyclosporine A decreases HPA axis activity and plasma noradrenaline levels in healthy male volunteers [J].
Albring, Antje ;
Wendt, Laura ;
Harz, Nino ;
Engler, Harald ;
Wilde, Benjamin ;
Witzke, Oliver ;
Schedlowski, Manfred .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2014, 126 :73-76
[9]  
Anghel Daniela, 2013, Maedica (Bucur), V8, P170
[10]  
[Anonymous], 2006, MYCOPHENOLATE MOFETI